%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2018-01-15T20:18:13+05:30
2018-01-15T20:18:14+05:30
2018-01-15T20:18:14+05:30
Adobe InDesign CS6 (Macintosh)
uuid:cdbfcb0b-4702-f347-8302-aff23a8792f4
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.id:58D2CA6A252068118083B4CAD1F9ECF6
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2018-01-15T20:18:13+05:30
xmp.iid:317CBE0D242068118083B4CAD1F9ECF6
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.did:01801174072068118DBB881A9EDFAAFA
default
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
6 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
26 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
11 0 0 11 579.4999 54.4294 Tm
(3)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
BT
/TT0 1 Tf
0.139 Tw 11 0 0 11 45 697.9917 Tm
[(of )0.5(this device, it was recommended )-0.6(that )0.5(a neurolo)]TJ
0 Tw 23.122 0 Td
(-)Tj
0.104 Tw -23.122 -1.182 Td
[(gist and cardiologist )-0.6(agree on the indication )-0.6(prior to )]TJ
0.347 Tw 0 -1.182 TD
[(proceeding )-0.6(with implantation. Contraindications )-1(to )]TJ
0.211 Tw 0 -1.182 TD
[(the device include )-0.6(intra-cardiac mass, vegetations, )]TJ
0.254 Tw 0 -1.182 TD
(tumor or thrombus at the implant site, anatomical )Tj
0.152 Tw T*
[(limitations, )-0.8(active endocarditis, )-1.1(untreated )-0.7(infections, )]TJ
0.198 Tw T*
(or other sources of right-to-left shunts. In addition, )Tj
-0.021 Tw T*
[(patients with nickel )-0.6(allergy )-0.7(may have an allergic )-0.9(reac)]TJ
0 Tw (-)Tj
0.126 Tw T*
(tion to the device that may last up to 60 days after )Tj
-0.03 Tw 0 -1.182 TD
[(device implantation. Due to )0.6(the FDA)74.2(\222)17.9(s )0.6(approval of )0.6(this )]TJ
0.039 Tw 0 -1.182 TD
[(device )-0.9(and )-0.7(the latest results, predominantly )-1.5(from the )]TJ
-0.101 Tw T*
[(RESPECT)17.9( and )-0.7(REDUCE )-0.9(trials, )-0.6(there is an expectation )]TJ
0 Tw T*
[(that )0.6(the )0.6(guide)-0.8(lines for )0.6(PFO )0.6(closure will be updated to )]TJ
/C2_0 1 Tf
T*
[<0055004800C00048004600570003>-36.6<0057004B0048005600480003>-36.7<00470044005700440003>-36.8<0044005100470003>-36.9<00480051004700520055005600480003>-37.2<004C005700560003>-36.4<00580056004800110003>-18.6<0037004B0048005500480003>-36.7<0055004800500044004C00510003>]TJ
/TT0 1 Tf
-0.029 Tw 0 -1.182 TD
[(ongoing )-0.6(of)18.1(f-label uses for )0.5(PFO )0.9(closure in decompres)]TJ
0 Tw 23.122 0 Td
(-)Tj
0.055 Tw -23.122 -1.182 Td
(sion sickness, migraines, and platypnea-orthodeoxia )Tj
0.156 Tw 0 -1.182 TD
[(syndrome. With regard to decompression )-0.8(sickness, )]TJ
0.132 Tw T*
[(the data seems to favor closure; however)54.4(, )0.5(this rep)]TJ
0 Tw (-)Tj
0.058 Tw T*
[(resents a small patient population )-0.8(of divers suf)18.1(fering )]TJ
0.185 Tw T*
[(from decompression )-1(sickness who have also been )]TJ
0.183 Tw 0 -1.182 TD
[(diagnosed )-0.7(with a PFO. )19(The much larger subset of )]TJ
/C2_0 1 Tf
0 Tw 0 -1.182 TD
[<005300440057004C00480051005700560003>-31.8<005A004C0057004B0003>-31.7<0050004C004A00550044004C0051004800560003>-32.3<005A004C0057004B0003>-31.5<00440058005500440003>-31.8<004B0044005900480003>-31.8<004F0048005600560003>-31.7<0047004800BF0051004C0057004C005900480003>]TJ
/TT0 1 Tf
0.103 Tw T*
[(evidence, )-1(and )-0.7(the evidence )-1.2(is not strong )-0.6(enough )-1.1(to )]TJ
0 Tw T*
(recommend placement in these patients. )Tj
0.392 Tw 1.636 -1.773 Td
[(In summary)73.9(, the )54.9(AMPLA)74.1(TZER PFO Occluder )]TJ
-0.08 Tw -1.636 -1.182 Td
[(received )-1(FDA)55.2( approval )-1.2(in 2016 )-0.6(for cryptogenic )-0.9(strokes )]TJ
-0.007 Tw T*
(with a right-to-left shunt in young patients for second)Tj
0 Tw 23.122 0 Td
(-)Tj
/C2_0 1 Tf
-23.122 -1.182 Td
[<00440055005C0003>-248.4<0053005500480059004800510057004C0052005100110003>-230.2<0037004B0048005500480003>-248.5<004C00560003>-248.4<00500052005500480003>-248.5<00480059004C004700480051004600480003>-249.2<005200490003>-248.2<004500480051004800BF00570003>]TJ
/TT0 1 Tf
0.146 Tw T*
(in patients with moderate or large shunt size, atrial )Tj
-0.01 Tw T*
[(septal aneury)-0.6(sm, and with continuation )-0.9(of antiplatelet )]TJ
0.12 Tw 0 -1.182 TD
[(agents follow)-0.7(ing device implantation. )-0.7(Rates of atrial )]TJ
/C2_0 1 Tf
0 Tw 0 -1.182 TD
[<00BF00450055004C004F004F00440057004C005200510003>-378.6<005A0048005500480003>-377.9<0056004C004A0051004C00BF0046004400510057004F005C0003>-378.4<004C005100460055004800440056004800470003>-378.4<004C00510003>-377.8<005300440057004C00480051005700560003>]TJ
/TT0 1 Tf
0.129 Tw T*
[(receiving )-1.1(device implantat)-0.6(ion. )17.6(The use of long )-0.8(term )]TJ
0.008 Tw T*
(event monitoring was not routinely performed prior to )Tj
0 Tw T*
(implantation.)Tj
/TT1 1 Tf
-0.005 Tc 0.005 Tw 10 0 0 10 63 229.9917 Tm
(Keywords:)Tj
/TT0 1 Tf
-0.068 Tw 11 0 0 11 113.673 229.9917 Tm
[( patent )0.5(foramen ovale, )0.5(right )0.5(to left shunt,)-4.8( )]TJ
0 Tw -6.243 -1.182 Td
(cryptogenic stroke)Tj
ET
0 0 0 1 K
q 1 0 0 1 327 705.5171 cm
0 0 m
258 0 l
S
Q
q 1 0 0 1 327 637.0171 cm
0 0 m
258 0 l
S
Q
BT
/TT2 1 Tf
0 Tc 10 0 0 10 327 687.0171 Tm
(From:)Tj
/TT0 1 Tf
10.5 0 0 10.5 355.3301 687.0171 Tm
[( Department of Internal Medicine at )17.1(T)111(exas )17.9(T)111(ech )]TJ
-2.698 -1.19 Td
[(University Health Sciences Center)53.3(, Lubbock, )18(TX)]TJ
/TT2 1 Tf
10 0 0 10 327 662.0171 Tm
(Submitted:)Tj
/TT0 1 Tf
10.5 0 0 10.5 379.2168 662.0171 Tm
( )Tj
(1/7/2018)Tj
/C2_1 1 Tf
10 0 0 10 327 649.5171 Tm
<00260052005100C0004C0046005700560003005200490003004C0051005700480055004800560057001D>Tj
/TT2 1 Tf
10.5 0 0 10.5 424.2266 649.5171 Tm
( )Tj
/TT0 1 Tf
(none)Tj
ET
q
0 0 630 810 re
W n
BT
/T1_1 1 Tf
13 0 0 13 327 602.5171 Tm
(R)Tj
9.1 0 0 9.1 335.6709 602.5171 Tm
(EFE)Tj
/Span<>> BDC
(R)Tj
EMC
(ENCES)Tj
ET
Q
BT
/T1_0 1 Tf
-0.03 Tc 0.03 Tw 10 0 0 10 327 577.5171 Tm
[(1)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.126 Tw 1.5 0 Td
[(Hagen PT)99.9(, Sholz DG, Edw)24.9(ards )30(WD)59.9(. Incidence and size of )]TJ
0.082 Tw 0 -1.2 TD
[(patent foramen o)44.9(v)24.9(ale during the \037rst 10 decades of line: an )]TJ
-0.058 Tw T*
[(autopsy )0.5(study )0.5(of )0.5(965 )0.5(nor)-19.7(mal )0.5(hear)-19.8(ts. )]TJ
/T1_3 1 Tf
14.27 0 Td
[(Mayo )0.5(Clin )0.5(Pr)45(oc)]TJ
/T1_2 1 Tf
[( )0.5(1984;59:)]TJ
0 Tw ( )Tj
-14.27 -1.2 Td
(17\22620.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.5 -1.2 Td
[(2)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.113 Tw 1.5 0 Td
[(Mojadidi MK, )29.9(W)39.9(inok)9.7(er JS, Rober)-19.8(ts SC, et al. )55.1(Accurac)15(y of )]TJ
0.04 Tw T*
[(con)39.8(v)14.9(entional transthoracic echocardio)24.9(g)-19.8(raph)29.9(y for the diagno)]TJ
0 Tw (-)Tj
0.02 Tw T*
[(sis of intracardiac right-to-left shunt: a meta-anal)25(ysis of pro)]TJ
0 Tw (-)Tj
T*
[(specti)24.9(v)14.9(e studies. )]TJ
/T1_3 1 Tf
[(Ec)14.9(hocar)36.9(dio)24.9(gr)44.9(aph)19.8(y)]TJ
/T1_2 1 Tf
( 2014;31:1036\2261048.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.5 -1.2 Td
[(3)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc -0.013 Tw 1.5 0 Td
[(Mojadidi MK, Bo)24.9(gush N)24.9(, Caceres JD)59.9(, et al. Diagnostic accu)]TJ
0 Tw (-)Tj
0.043 Tw T*
[(rac)14.9(y of transesophageal echocardio)25(g)-19.8(ram for the detection of )]TJ
0 Tw 24.3 0 Td
( )Tj
-0.015 Tc -0.072 Tw -24.3 -1.2 Td
[(patent foramen o)44.9(v)24.9(ale: a meta-anal)24.9(ysis. )]TJ
/T1_3 1 Tf
0.015 Tw [(Ec)14.9(hocar)36.9(dio)24.9(gr)44.9(aph)19.8(y)54.9(.)]TJ
/T1_2 1 Tf
-0.072 Tw ( 2014;)Tj
0 Tc 0 Tw 24.3 0 Td
( )Tj
-24.3 -1.2 Td
(31:752\226758.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.5 -1.2 Td
[(4)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.113 Tw 1.5 0 Td
[(Mojadidi MK, Rober)-19.7(ts SC, )29.9(W)39.8(inok)9.8(er JS, et al. )55.1(Accurac)15(y of )]TJ
0.095 Tw T*
(transcranial Doppler for the diagnosis of intracardiac right-)Tj
-0.02 Tw T*
[(to-left shunt: a bi)25(v)24.8(ariate meta-anal)25(ysis of prospecti)24.9(v)14.9(e studies. )]TJ
/T1_3 1 Tf
0 Tw T*
[(J)39.8(A)59.8(CC Car)36.9(dio)29.8(vasc Ima)19.8(ging)]TJ
/T1_2 1 Tf
( 2014;7:236\226250.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.5 -1.2 Td
[(5)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc -0.008 Tw 1.5 0 Td
[(Dahl\366f, CGH, S\370nder)17.9(g)4.9(aard L, Hannam PH. )50.1(The rationale for )]TJ
0.021 Tw T*
[(PFO closure: a series of ar)17.8(guments for and ag)4.9(ainst. )]TJ
/T1_3 1 Tf
0 Tw [(V)139.9(ascular )]TJ
T*
[(Disease Mana)19.8(g)9.8(ement)]TJ
/T1_2 1 Tf
( 2009;6\(3\):80\22690.)Tj
/T1_0 1 Tf
-0.035 Tc 0.035 Tw -1.5 -1.2 Td
[(6)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
-0.005 Tc 0.082 Tw 1.5 0 Td
[(Furlen )55.1(AJ)59.9(, Reisman M, Massaro J)59.8(, et al. Closure or medical)-5( )]TJ
0.235 Tw T*
[(therap)29.8(y for cr)-19.8(ypto)24.9(genic strok)9.8(e with patent foramen o)44.9(v)24.9(ale.)-5( )]TJ
/T1_3 1 Tf
0 Tw T*
(N)Tj
/Span<>> BDC
( )Tj
EMC
(Engl J Med)Tj
/T1_2 1 Tf
( 2012;366:991\226999.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.5 -1.2 Td
[(7)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.013 Tw 1.5 0 Td
[(Meier B)29.8(, Kalesan B)29.8(, Mattle H, et al. P)39.8(ercutaneous closure of )]TJ
-0.032 Tw T*
[(patent foramen o)45(v)24.9(ale in cr)-19.8(ypto)24.9(genic embolism. )]TJ
/T1_3 1 Tf
(N Engl J Med)Tj
/T1_2 1 Tf
0 Tw ( )Tj
T*
(2013;368:1083\2261091.)Tj
/T1_0 1 Tf
-0.05 Tc 0.05 Tw -1.5 -1.2 Td
[(8)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
-0.02 Tc -0.017 Tw 1.5 0 Td
[(Car)-29.8(roll JD)59.8(, Sa)35(v)14.9(er JF)129.9(, )49.4(Thaler DE, et al. Closure of patent foramen)-20( )]TJ
-0.032 Tw T*
[(o)44.9(v)24.9(ale vs. medical therap)29.8(y after cr)-19.8(ypto)24.9(genic strok)9.8(e. )]TJ
/T1_3 1 Tf
(N Engl J Med)Tj
/T1_2 1 Tf
0 Tc 0 Tw 24.3 0 Td
( )Tj
-0.02 Tc 0.02 Tw -24.3 -1.2 Td
(2013;268:1091\2261100.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.5 -1.2 Td
[(9)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.037 Tw 1.5 0 Td
[(S\370nder)17.8(g)4.9(aard L, Kasner SE, Rhodes JF)129.9(, et al. P)14.9(atent foramen )]TJ
0.108 Tw T*
[(o)44.9(v)24.9(ale closure or antiplatelet therap)29.8(y for cr)-19.7(ypto)24.9(genic strok)9.8(e. )]TJ
/T1_3 1 Tf
0 Tw T*
(N)Tj
/Span<>> BDC
( )Tj
EMC
(Engl J Med )Tj
/T1_2 1 Tf
(2017;377:1033\2261042.)Tj
ET
endstream
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 45 54.1778 Tm
(The Southwest Respiratory and Critical Care Chronicles 2018;6\(22\):1\226\
3)Tj
ET
endstream
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 45 68.8957 cm
0 0 m
540 0 l
S
Q
10 M
q 1 0 0 1 45 740.2762 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 45 751.5262 Tm
[(Patent Foramen Ovale Closure: T)91.1(o Do or Not to Do!)]TJ
/Span<>> BDC
( )Tj
EMC
62.22 0 Td
(Ansari et al.)Tj
ET
endstream
endobj
31 0 obj
<>
endobj
32 0 obj
<>
endobj
33 0 obj
<>stream
H\ۊ0l/HAb[b`+1D{S/dL>ծeF, xnI*mon"BqL3FQ2ixނл|UVF2e)-tX 2Zey?/;e|.dnƌ&(b\,.J;Oˮn(RJc sB|f>#+cE9jϼ'V̊X3kb0ccEƾfH:cΈ⊹">1Kf/M^y2d9s7gr]*q9'sG>u64KT'~
endstream
endobj
34 0 obj
<>stream
HlU TUGAYP .+AE4ʢ)`ѨQu4Qqc3F".qC.#,K2M99INu[hEpLGk